Literature DB >> 15557870

[Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy].

S Scheer1, C Morel, O Touzeau, J A Sahel, L Laroche.   

Abstract

Proliferative vitreoretinopathy (PVR) is the major cause of retinal detachment surgery failure. Many adjuvants were studied in vitro and on animals, some were studied on humans. Daunomycin seems to reduce PVR recidivism. 5-FU and steroids are nontoxic but their efficacy is not clear. Heparin reduced postoperative inflammation and seems to reduce PVR recidivism when associated with 5-FU. Associating heparin and steroids seems to reduce PVR in some groups of patients (aphakic, anterior PVR). Colchicine and retinoic acid per os are ineffective, silicone oil is effective as an internal tamponade but not as an adjuvant of PVR. Currently, no molecule has proven efficacy as an adjunctive treatment of PVR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557870     DOI: 10.1016/s0181-5512(04)96264-x

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  7 in total

1.  A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.

Authors:  Huiyuan Hou; Kristyn Huffman; Sandy Rios; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

2.  Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Authors:  Huiyuan Hou; Alejandra Nieto; Feiyan Ma; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

3.  Three hundred and sixty degree retinotomy for retinal detachments with severe proliferative vitreoretinopathy.

Authors:  Steven Garnier; Ahmed Rahmi; Cédric Grasswil; Laurent Kodjikian
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-16       Impact factor: 3.117

Review 4.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

Review 5.  [Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].

Authors:  F Schaub; A M Abdullatif; S Fauser
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

6.  Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by the human lectin galectin-1.

Authors:  Claudia S Alge-Priglinger; Sabine André; Thomas C Kreutzer; Cornelia A Deeg; Anselm Kampik; Marcus Kernt; Harald Schöffl; Siegfried G Priglinger; Hans-Joachim Gabius
Journal:  Mol Vis       Date:  2009-10-23       Impact factor: 2.367

7.  In vitro vitamin K3 effect on conjunctival fibroblast migration and proliferation.

Authors:  I Pinilla; L B Izaguirre; F J Gonzalvo; E Piazuelo; M A Garcia-Gonzalez; A I Sanchez-Cano; F Sopeña
Journal:  ScientificWorldJournal       Date:  2014-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.